<table>
<thead>
<tr>
<th>項目</th>
<th>内容</th>
</tr>
</thead>
<tbody>
<tr>
<td>コレゲーション・フィブリンオシス異常</td>
<td>家族性アミロイドポリネーロパシー</td>
</tr>
<tr>
<td>著者</td>
<td>胆沢, 起一; 野沼, 賢二郎; 髙田, 公秀; 伊賀, 昭; 増戸, 大輔; 野崎, 芝郎; 宮崎, 聡; 岩田, 昭和; 沢田, 保治</td>
</tr>
<tr>
<td>引用</td>
<td>Amyloid, 19(3): 129-132</td>
</tr>
<tr>
<td>発行日</td>
<td>2012-09</td>
</tr>
<tr>
<td>タイプ</td>
<td>周刊 冊子</td>
</tr>
<tr>
<td>リファレンス</td>
<td>URL: <a href="http://hdl.handle.net/2297/32460">http://hdl.handle.net/2297/32460</a></td>
</tr>
</tbody>
</table>

KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。
KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。
著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。

*KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。
*KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。
著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。

URL: http://dspace.lib.kanazawa-u.ac.jp/dspace/
Original article

ID DAMY-2011-0091

Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy

Ryoichi Takahashi¹, Kenjiro Ono¹, Tokuhei Ikeda¹, Akio Akagi¹, Daisuke Noto¹, Ichiro Nozaki¹, Kenji Sakai¹, Hidesaku Asakura², Kazuo Iwasa¹, Masahito Yamada¹

¹Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan.

²Department of Internal Medicine (III), Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan.

Correspondence: Masahito Yamada, MD, PhD, Professor & Chairman, Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8640, Japan; Tel: +81-76-265-2290; Fax:
+81-76-234-4253; E-mail: m-yamada@med.kanazawa-u.ac.jp

Running Head: Coagulation and fibrinolysis abnormalities in FAP
Abstract

Objective. Familial amyloid polyneuropathy (FAP) is an autosomal dominant form of hereditary amyloidosis. Several studies reported coagulation factor X deficiency and excessive fibrinolysis in immunoglobulin light chain amyloidosis. However, few have investigated coagulation and fibrinolysis in FAP. The objective of this study was to determine abnormalities in plasma biomarkers of coagulation and fibrinolysis in FAP.

Methods. We prospectively recruited eight FAP patients with transthyretin mutations and ten age-matched control patients with other neuropathies in our university. We examined plasma biomarkers of coagulation and fibrinolysis including prothrombin time, activated partial thromboplastin time, fibrinogen, fibrin/fibrinogen degradation products, D-dimer, α2-antiplasmin, antithrombin, plasminogen, thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, prothrombin fragment 1+2, and coagulation factor X. The Mann-Whitney U test was performed for statistical comparisons between FAP and control groups.
Results. FAP patients exhibited significantly decreased levels of coagulation factor X, plasminogen and α2-antiplasmin, and significantly increased levels of prothrombin fragment 1+2 compared to control patients.

Conclusion. Our results indicate abnormalities of coagulation and fibrinolysis in FAP patients.

Keywords: amyloidosis, coagulation factor, prothrombin fragment, α2-antiplasmin, plasminogen

Abbreviations: α2-AP = α2-antiplasmin; APTT = activated partial thromboplastin time; AL amyloidosis = immunoglobulin light chain amyloidosis; AT = antithrombin; CIDP = chronic inflammatory demyelinating neuropathy; F1+2 = plasma prothrombin fragment 1 + 2; FAP = familial amyloid polyneuropathy; Fbg = fibrinogen; FDPs = fibrin/Fbg degradation products; FVIIa = activated coagulation factor VII; FX = coagulation factor X;
PAP = plasmin-α2-antiplasmin complex; PT = prothrombin time; TAT = thrombin-antithrombin complex; TTR = transthyretin
Introduction

Familial amyloid polyneuropathy (FAP) is an autosomal dominant form of hereditary amyloidosis. Amyloidogenic mutated transthyretin (TTR) is the most common FAP-related protein worldwide [1]. Several studies reported coagulation factor X (FX) deficiency and excessive fibrinolysis in immunoglobulin light chain amyloidosis (AL amyloidosis) patients [2-4]. However, few have investigated coagulation and fibrinolysis in FAP. Most researchers did not observe coagulation abnormalities in FAP patients because of low incidence of hemorrhagic events [5]. Here we examined coagulation and fibrinolysis in FAP and observed decreased levels of FX, plasminogen, and α2-antiplasmin (α2-AP) and elevated levels of plasma prothrombin fragment 1 + 2 (F1+2).

Patients and methods

FAP patients

We investigated coagulation and fibrinolysis in eight consecutive FAP patients admitted to our hospital from 2004 to 2011. In our district, FAP with a TTR Val30Met
mutation was endemic [6], and a FAP pedigree with rare TTR Leu58Arg mutation was present [7]. Diagnoses were confirmed in all patients by positive family history, clinical and neurophysiological examinations, tissue biopsies of the sural nerve and gastrointestinal tract demonstrating amyloid deposits, and gene analysis indicating the TTR Val30Met (n = 7) or Leu58Arg mutations (n = 1). All patients were from separate kinships. Patient age ranged from 34 to 77 years (median age: 66 years); six of the eight patients were males and two were females. Three patients experienced hemorrhagic events: one had intestinal hemorrhage, one had hematuria and a hemorrhagic kidney cyst on abdominal computed tomography, and one had seminal vesicle hemorrhage; no patient experienced serious hemorrhagic events requiring blood transfusion or resulting in death. All patients had no genetic abnormalities of coagulation and fibrinolysis. All patients had no liver dysfunction and showed normal levels of transaminase, albumin, and choline esterase (data not shown).

**Control patients**

We prospectively recruited control patients with peripheral neuropathy at our hospital. Each peripheral neuropathy was diagnosed by clinical, laboratory, and neurophysiological
examinations, and nerve biopsy. We excluded patients being administered anticoagulation
drugs and those having severe hepatic injury or innate coagulopathy. The age of ten
control patients with peripheral neuropathies ranged from 57 to 67 years (median age: 61
years; not significantly different from that of FAP patients). Diagnoses included alcoholic
neuropathy (n = 3), diabetic neuropathy (n = 2), vasculitic neuropathy (n = 1), Crow-Fukase
syndrome (n = 1), neuropathy with anti-myelin-associated glycoprotein antibody (n = 1),
chronic inflammatory demyelinating neuropathy (CIDP) (n = 1), and Charcot-Marie-Tooth
disease (n = 1).

Coagulation and fibrinolysis tests

This study was approved by the medical ethical committee of our university. After
obtaining written informed consent, blood samples were obtained from all FAP and control
patients. Plasma samples were analyzed for prothrombin time (PT), activated partial
thromboplastin time (APTT), fibrinogen (Fbg), fibrin/Fbg degradation products (FDPs),
D-dimer, α2-AP, antithrombin (AT), plasminogen, thrombin-antithrombin complex (TAT),
plasmin-α2-antiplasmin complex (PAP), F1+2, and FX. PT and APTT were measured by
light scattering spectroscopy using diagnostic kits (PT: Thromborel® S, Siemens Healthcare Diagnostics, Inc. APTT: Actin FSL, Siemens Healthcare Diagnostics, Inc.). Fbg and FX were measured by the coagulation time method using reagents (Fbg: Fibrinogen determination; Siemens Healthcare Diagnostics, Inc. FX: HemosIL Factor X deficient plasma and HemosIL Recombiplastin; Mitsubishi Chemical Medience Co., Ltd., Japan).

FDP was measured by latex photometric immunoassay using a diagnostic kit (Nanopia® P-FDP; Sekisui Medical Co., Ltd., Japan). AT, α2-AP, and plasminogen were measured using synthetic chromogenic peptide substrate (AT: Test Team® S AT III, Sekisui Medical Co., Ltd., Japan. α2-AP: Test Team® S APL; Sekisui Medical Co., Ltd., Japan. Plasminogen: test team® S PLG; Sekisui Medical Co., Ltd., Japan). TAT, PAP, and F1+2 were measured by enzyme immunoassay, latex agglutination turbidimetric immunoassay, and enzyme-linked immunosorbent assay using diagnostic kits (TAT: TAT S; TFB Co., Ltd., Japan. PAP: LPIA-S PPI II; Mitsubishi Chemical Medience Co., Ltd., Japan. F1+2: Enzygnost®F1+2 Monoclonal; Siemens Healthcare Diagnostics, Inc., Japan), respectively.

The two patient groups were statistically compared using the Mann-Whitney U test.
Statistical analyses were performed using software package StatView version 5.0. \( P \) values <0.05 were considered significant.

Results

The table 1 shows the coagulation and fibrinolysis test results of FAP and control patients. The levels of \( \alpha_2 \)-AP, plasminogen, F1+2, and FX were abnormal in the FAP group but not in the control group. FAP patients exhibited significantly decreased levels of \( \alpha_2 \)-AP \( (p = 0.039) \), plasminogen \( (p = 0.0037) \), and FX \( (p = 0.0010) \), and significantly elevated levels of F1+2 \( (p = 0.019) \) compared with control patients.

Some FAP patients also presented with prolonged PT \( (n = 2) \), elevated TAT level \( (n = 1) \), and mildly elevated PAP levels \( (n = 4) \). No abnormalities were observed in levels of Fbg, FDP, or D-dimer in FAP patients.

Some control patients exhibited prolonged PT \( (n = 1) \), elevated TAT levels \( (n = 2) \), and elevated levels of F1+2 \( (n = 4) \). However, no abnormalities were observed in levels of \( \alpha_2 \)-AP, Plg, Fbg, FDP, D-dimer, or FX.
Discussion

Our results indicate coagulation and fibrinolysis abnormalities in FAP patients. The figure 1 shows the coagulation and fibrinolysis cascades and the abnormalities observed in FAP patients. For coagulation markers, we observed significant elevation of F1+2 and decrease of FX in FAP patients. F1+2 is an activation peptide generated during prothrombin conversion to thrombin, and the elevation of F1+2 indicates in vivo thrombin generation, which means the activation of coagulation. Among fibrinolysis markers, we observed significantly decreased levels of α2-AP and plasminogen. PAP was elevated in FAP patients compared to normal value, but this elevation of PAP was not significant. The decreased levels of α2-AP and plasminogen indicate the activation of fibrinolysis. Our FAP patients had no liver dysfunction, congenital blood coagulation disorders, or thrombotic disorders, such as atherosclerosis, thromboembolism, inflammation, cancer, sepsis, and atrial fibrillation [8].

As for the mechanisms underlying the activation of coagulation and fibrinolysis in
FAP, we speculate that the injury of vascular endothelial cells by amyloid deposits might lead to expression of tissue factor and initiate the extrinsic pathway of the clotting cascades, activating coagulation. The activation of coagulation by amyloid deposits might trigger secondary fibrinolysis. However, as discussed below, further investigations are necessary to understand the mechanism by which activation of coagulation and fibrinolysis occurs in FAP patients.

F1+2 and TAT are biomarkers of thrombosis, and, commonly, F1+2 plasma concentration is correlated with that of TAT in thrombosis [9]. In our study, TAT levels were not elevated despite thrombin neutralization by antithrombin-mediated TAT generation. The reason why TAT was not elevated in FAP patients might be explained by the shorter half-life of TAT (5 min versus 90 min for F1+2) [10-11]. The decrease of $\alpha_2$-AP and plasminogen could indicate the activation of fibrinolysis; however, PAP was not significantly elevated. It was reported that the levels of PAP were significantly elevated in the patients of AL and AA amyloidoses, which would be related to pathological bleeding, but the PAP levels were not elevated in FAP [2], compatible with our results; this would be
consistent with less severe bleeding tendency in FAP compared with AL and AA amyloidoses [3]. In our study, we found the mild activation of coagulation and fibrinolysis in FAP patients. The half-life (0.5 days) of PAP is shorter compared with that of plasminogen (2.2 days) and $\alpha_2$-AP (2.6 days) [12-13] during the activation of fibrinolysis. The shorter half-life of PAP as well as mild activation of fibrinolysis might be related to insignificant elevation of PAP in FAP. Further, it remains to be determined why the FDP levels were not elevated in spite of activation of fibrinolysis in FAP patients, though we speculate that the FDP levels were unchanged because the activation of fibrinolysis was very mild.

Decreased FX was also observed in FAP patients. Decrease of FX may be explained by FX consumption due to excessive coagulation. On the other hand, deficiencies of coagulation factors such as FX have been reported in AL amyloidosis [3]. FX deficiency has been demonstrated to be due to in vivo binding of FX to the amyloid fibrils [14]. FX binding to amyloid fibrils may occur in FAP as well as AL amyloidosis. However, there is no immunohistochemical proof of FX binding to FAP amyloid deposits.
Thus, we first demonstrated that the coagulation and fibrinolysis cascades were activated in FAP. Our study has certain limitations. The sample size was relatively small. Patients with AL or other amyloidoses were not examined. A prospective study with a large sample size should be conducted to confirm coagulation and fibrinolysis abnormalities in FAP.

Acknowledgments

This study was partly supported by a grant for the Amyloidosis Research Committee from the Ministry of Health, Labour and Welfare, Japan.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
References


Shibata-Hamaguchi A, Frukawa Y, Yanase D, Ishida C, Sakajiri K, Yamada M.


Table 1. Tests for coagulation and fibrinolysis in FAP and control patients.

<table>
<thead>
<tr>
<th></th>
<th>Normal range</th>
<th>FAP</th>
<th>Other neuropathies</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/Female</td>
<td>6/2</td>
<td>6/4</td>
<td></td>
<td>0.267</td>
</tr>
<tr>
<td>Age</td>
<td>66.5 ± 5.0</td>
<td>61.5 ± 2.88</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>PT (s)</td>
<td>10.5-13.5</td>
<td>12.3 ± 0.59</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>APTT (s)</td>
<td>24.3-36.0</td>
<td>28.3 ± 1.81</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>Fbg (mg/dL)</td>
<td>150-400</td>
<td>265.5 ± 23.3</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>FDPs (μg/mL)</td>
<td>&lt;4</td>
<td>1.6 ± 0.58</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>α2-AP (%)</td>
<td>85-115</td>
<td>↓ 80.0 ± 5.13</td>
<td>(n = 6)</td>
<td>(n = 8)</td>
</tr>
<tr>
<td>AT (%)</td>
<td>70-130</td>
<td>92.0 ± 6.75</td>
<td>(n = 7)</td>
<td>(n = 5)</td>
</tr>
<tr>
<td>Plg (%)</td>
<td>75-125</td>
<td>↓ 76.0 ± 6.75</td>
<td>(n = 6)</td>
<td>(n = 9)</td>
</tr>
<tr>
<td>TAT (ng/mL)</td>
<td>&lt;3.0</td>
<td>1.3 ± 0.3</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>PAP (μg/mL)</td>
<td>&lt;0.8</td>
<td>1.0 ± 0.16</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>F1+2 (pmol/L)</td>
<td>69-229</td>
<td>↑ 281.0 ± 51.4</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
<tr>
<td>FX (%)</td>
<td>70-130</td>
<td>↓ 62.0 ± 3.5</td>
<td>(n = 8)</td>
<td>(n = 10)</td>
</tr>
</tbody>
</table>

Values are median values ± quartile deviation. *p < 0.05, **p < 0.01.
Figure legend:

Figure 1. Coagulation and fibrinolysis cascades.

FAP patients showed elevated F1+2 and decreased FX, plasminogen and α2-AP levels, indicating activation of coagulation and fibrinolysis.
The system of coagulation

- Vascular injury
  - FVIIa + Tissue factor
  - prothrombin
    - FXa
    - FX
    - F1 +2↑
  - TAT
  - thrombin
  - fibrinogen
  - fibrin
  - FDPs

The system of fibrinolysis

- plasminogen ↓
  - plasmin
    - α2-AP ↓
    - PAP